Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Dr. |
RCV003330244 | SCV004037271 | pathogenic | Pitt-Hopkins syndrome | 2021-07-09 | criteria provided, single submitter | clinical testing | The deletion was verified and characterized further by complementary methods (array revision, MLPA, nanopore sequencing) allowing identification of breakpoints with high probability. The deletion leads to the loss of a 65bp exon (exon 6 in isoform 1) in most isoforms, in a few isoforms to the loss of their first two exons, but also affects only the 5'UTR in some isoforms. However, disruptive variants upstream (and also downstream) have already been shown to be pathogenic. The deletion most likely leads to a non-functional gene product, has not been detected in the general population (gnomAD SVs v2.1; approx. 10,000 individuals) and has also been excluded in the parents (thus is assumed to be de novo). Thus, it is classified as pathogenic. |